Business
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
LONDON, Sept. 12, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, Sept. 12, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (\"Virax\" or the \"Company\") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of an early access program for the research-use-only (\"RUO\") of its proprietary SARS-Cov-2 ViraxImmune T-cell-based test. The company will host a webinar on September 20, 2023 at 10 AM EST.\n\n \n \n \n \n \n \n\n \nThe early access program offers select research groups an opportunity to be at the forefront of immune assessment advancements. The RUO form of Virax's T-cell-based test is designed to assess the activation of memory T-cells specific to the SARS-Cov-2 by combining an ELISpot assay with a peptide pool covering specific protein parts of the virus. The test requires the isolation of peripheral blood mononuclear cells (\"PBMCs\") from blood samples that are then seeded onto the Company's pre-coated ELISpot plate. The cytokines secreted by the cells upon stimulation with the peptide pool are immediately captured by the antibodies bound to the plate and detected through a series of reactions with antibodies and enzyme-substrate interactions, resulting in visible spots. Each spot represents a single cytokine-secreting cell, allowing for high-resolution analysis of immune responses at the cellular level. This test provides a quantitative assessment of immune response, which will help to develop a deeper understanding of an individual's immune profile. The Company's tests are compatible with a wide range of ELISpot readers, ensuring ease of use without requiring additional costly laboratory equipment.\n\"We are thrilled to launch this early access program for the RUO of our proprietary ViraxImmune T-cell based test,\" said Mr. James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs. \"We look forward to working with early adopters who also share the vision to be at the frontier of cutting-edge diagnostics and bringing value to human immune health.\"\n\"We are excited to get our proprietary T-cell-based tests in the hands of researchers as demand is growing for T-cell tests due to its advantages when compared to antigen and antibody-based tests in the context of determining long-term immunity to viral threats,\" commented Dr. Tomasz George, Chief Scien...